Cancer begins with damage to a cell’s DNA, but a single mutation almost never causes cancer on its own. The disease progresses through a series of distinct biological stages: a normal cell acquires genetic errors that make it grow unchecked, it recruits surrounding tissue to support that growth, it breaks through physical barriers, survives transit through the bloodstream, and colonizes a distant organ. Each step involves its own biology, and a failure at any step can halt the process entirely. Understanding the full chain helps explain why some cancers grow slowly and stay put for years while others spread aggressively within months.
How a Normal Cell Becomes Cancerous
Every cell in your body accumulates genetic changes over a lifetime, from copying errors during cell division to damage from UV light, tobacco smoke, or chronic inflammation. Most of these changes are harmless. Cancer starts when a cell picks up what researchers call “driver mutations,” genetic alterations that give the cell a survival or growth advantage over its neighbors. Only a small fraction of all the mutations a cell accumulates actually drive cancer forward, and these drivers can vary between cancer types and even between patients with the same diagnosis.1PubMed Central. Cancer driver mutations: predictions and reality
Driver mutations typically fall into two categories. Some activate genes that push cells to grow and divide (these genes, when mutated, are called oncogenes). Others disable genes that normally restrain growth or trigger damaged cells to self-destruct (tumor suppressor genes). A cell often needs hits in both categories before it truly goes rogue. Research has shown that these hits frequently involve not just point mutations but also changes in the number of gene copies: a cell might lose a chunk of chromosome carrying a tumor suppressor, or gain extra copies of an oncogene. These “two-hit” events, combining a point mutation with a copy number change, appear across cancer types and are now recognized as a widespread pattern in how cancers gain momentum.2PubMed Central. Copy number losses of oncogenes and gains of tumor suppressor genes generate common driver mutations
Genetic mutations are not the whole story. The same machinery that controls which genes are switched on or off in a cell can also be disrupted. Mutations in the genes that manage chemical tags on DNA (methylation patterns) or that package DNA around protein spools (histone modifications) can silence tumor suppressors or activate oncogenes without changing the DNA sequence itself.3PubMed Central. Cancer genetics and epigenetics: two sides of the same coin? This is why cancer is sometimes described as a disease of both genetics and epigenetics. One important wrinkle: a driver mutation can sit quietly in a cell for years, doing nothing harmful, and only become dangerous when additional mutations accumulate or when conditions in the tissue change. This latency period helps explain why cancer risk rises steeply with age.
How Tumors Fuel Rapid Growth
Once a cell has enough driver mutations to escape normal growth controls, it faces a practical problem: it needs enormous amounts of energy and raw materials to divide rapidly. Cancer cells solve this by rewiring their metabolism in a way that has puzzled scientists for nearly a century. Even when oxygen is plentiful and their energy-producing machinery is working fine, cancer cells overwhelmingly convert glucose into lactate rather than burning it efficiently through the normal oxygen-dependent pathway. This shift, known as the Warburg effect, is one of the most consistent features of cancer across virtually all tumor types.4PubMed Central. The Warburg Effect: How Does it Benefit Cancer Cells?
At first glance, this seems wasteful: aerobic glycolysis produces far less energy per glucose molecule than normal respiration. But the tradeoff gives cancer cells something they need more than peak efficiency. The intermediate molecules generated by this rapid glucose processing become building blocks for new cell membranes, proteins, and DNA, all the raw materials required for constant division. The metabolic switch is driven by altered signaling from growth factors, activation of oncogenes, loss of tumor suppressor function, and the low-oxygen conditions that develop inside growing tumors.5PubMed. The Warburg effect: essential part of metabolic reprogramming and central contributor to cancer progression The lactate that cancer cells dump into their surroundings also turns out to be useful: it acidifies the local tissue, which can suppress immune cells and make the area more hospitable for further tumor expansion.6Annual Review of Cancer Biology. Deciphering the Warburg Effect: Metabolic Reprogramming, Epigenetic Remodeling, and Cell Dedifferentiation
Building a Supportive Neighborhood
A tumor is not just a ball of cancer cells. It is an entire ecosystem, sometimes called the tumor microenvironment, that includes blood vessels, immune cells, structural scaffolding, and a population of co-opted support cells. Among the most important of these support cells are cancer-associated fibroblasts, which act as construction workers that remodel the tissue around the tumor. These fibroblasts deposit structural proteins like collagen and fibronectin, building a dense scaffold that physically supports the growing mass. They also produce enzymes that break down and rebuild the surrounding tissue, creating a self-reinforcing cycle where the tissue gets stiffer, which activates more remodeling signals, which makes it stiffer still.7PubMed Central. Cancer-associated fibroblasts in the tumor microenvironment: heterogeneity, crosstalk mechanisms, and therapeutic implications Through chemical signaling, these fibroblasts promote blood vessel growth, help the tumor resist treatment, and even encourage cancer cells to spread.8PubMed Central. Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives
No tumor can grow beyond a few millimeters without its own blood supply. Early in its development, a tumor exists in a state where it cannot recruit blood vessels and is limited in size. At some point, the balance between growth-promoting and growth-inhibiting signals tips, and the tumor begins actively stimulating the formation of new blood vessels from surrounding tissue. Researchers call this tipping point the “angiogenic switch.”9PubMed. The angiogenic switch in carcinogenesis Once the switch flips, tumors can grow rapidly and gain access to the bloodstream, which becomes a highway for potential spread. The new blood vessels that tumors build are often leaky and poorly structured, which is both a vulnerability that treatments try to exploit and a feature that helps cancer cells escape into circulation.
Breaking Through Barriers
For a cancer cell to spread beyond its original location, it first has to break through the physical barriers that keep normal tissues in place. Healthy cells in organs like the breast, colon, or lung are held together by molecular glue, particularly a protein called E-cadherin that acts like Velcro between neighboring cells. Cancer cells that are preparing to invade undergo a transformation where they lose this stickiness and gain the ability to move independently. They do this by activating genetic programs, driven by factors like Snail and Twist, that dial down E-cadherin production and shift the cell from a stationary, tightly connected shape to a mobile, elongated one.10PubMed. Snail promotes lymph node metastasis and Twist enhances tumor deposit formation through epithelial-mesenchymal transition in colorectal cancer11PubMed. Epithelial to mesenchymal transition: expression of the regulators snail, slug, and twist in pancreatic cancer
Mobility alone is not enough. Cells must also physically chew through the dense meshwork of proteins that forms the basement membrane, a thin but tough barrier separating tissue layers. Cancer cells accomplish this by deploying enzymes called matrix metalloproteinases that degrade the structural framework around them.12The FASEB Journal. Regulation of matrix metalloproteinase expression in tumor invasion One family member in particular, called MT1-MMP, localizes to the leading edge of invading cancer cells and works in partnership with other enzymes to break down collagen and other barrier proteins.13PubMed. Membrane-type 1 matrix metalloproteinase: a key enzyme for tumor invasion Research has identified a triad of membrane-anchored metalloproteinases that independently give cancer cells the ability to breach the basement membrane, extend invasive projections, and push through into surrounding tissue.14Genes & Development. A cancer cell metalloprotease triad regulates the basement membrane transmigration program
Surviving the Bloodstream
Entering the bloodstream is easy compared to surviving it. Cancer cells that break loose from a tumor and enter circulation, called circulating tumor cells, face a hostile environment. Blood flow exerts mechanical shearing forces, and without attachment to a solid surface, normal cells trigger a built-in self-destruct program called anoikis. Most circulating cancer cells die within hours. The rare survivors have developed tricks to resist this process. Studies in breast cancer cells have shown that the mechanical stress of blood flow itself can paradoxically help some cancer cells survive by triggering changes in a membrane protein called caveolin-1, which blocks both the internal and external cell-death pathways.15PubMed. Shear stress promotes anoikis resistance of cancer cells via caveolin-1-dependent extrinsic and intrinsic apoptotic pathways The shear stress also generates reactive oxygen species and nitric oxide signals that stabilize this protective protein, further boosting survival.16PubMed. Shear stress enhances anoikis resistance of cancer cells through ROS and NO suppressed degeneration of Caveolin-1
Cancer cells that travel in clusters rather than alone have a dramatically better chance of establishing metastases. In cancers such as breast and prostate cancer, clusters of circulating tumor cells seed new tumors at 20 to 100 times greater efficiency than single cells and are associated with worse patient outcomes.17Trends in Cancer. Circulating tumor cell clusters: biology, detection, and future clinical applications Clusters appear to benefit from mutual protection: the cells on the outside shield those on the inside from immune attack and shear forces, and the group can collectively express adhesion molecules that help them latch onto blood vessel walls at distant sites.
Preparing Distant Organs for Arrival
One of the more striking discoveries in cancer biology is that tumors do not simply scatter cells and hope for the best. They actively prepare distant organs to receive metastatic cells before those cells ever arrive. The primary tumor sends out tiny membrane-bound packages called exosomes, nano-sized vesicles loaded with proteins, RNA, and signaling molecules that travel through the bloodstream and are taken up by cells in distant organs like the lungs and liver.18PubMed Central. The Key Role of Exosomes on the Pre-metastatic Niche Formation in Tumors These exosomes reshape the receiving tissue into what researchers call a pre-metastatic niche, a landing pad that is primed to support incoming cancer cells.19PubMed Central. The Role and Mechanisms of Tumor-Derived Exosomes in the Formation of the Premetastatic Niche
Experimental work has demonstrated that the uptake of tumor-derived exosomes by cells in the lungs and liver occurs before metastatic cancer cells actually show up, and that this uptake triggers an inflammatory reaction that progressively shifts toward a pro-tumor environment as the niche matures.20PubMed Central. The capture of extracellular vesicles endogenously released by xenotransplanted tumours induces an inflammatory reaction in the premetastatic niche This finding fits neatly into a framework that cancer researchers have used for over a century. In 1889, surgeon Stephen Paget proposed the “seed and soil” hypothesis: metastasis depends on a favorable match between the cancer cell (the seed) and the receiving organ (the soil). Clinical data and decades of experimental research have confirmed that organ-preference patterns of metastasis reflect these interactions.21PubMed Central. The seed and soil hypothesis revisited–the role of tumor-stroma interactions in metastasis to different organs It is why breast cancer frequently spreads to bone, lung, and liver, while prostate cancer favors bone, and colorectal cancer heads for the liver. The pre-metastatic niche concept has updated Paget’s idea by showing that the soil is not simply receptive by accident. The primary tumor is actively fertilizing it from afar.22PubMed Central. Metastatic organotropism in peritoneal metastasis: Paget’s hypothesis revisited
Once circulating tumor cells reach a prepared organ, they face one last physical barrier: the blood vessel wall. To exit the bloodstream, cancer cells must adhere to the inner lining of blood vessels and squeeze or push through the endothelial cell layer in a process called extravasation.23PubMed Central. Visualizing cancer extravasation: from mechanistic studies to drug development The cells that successfully complete this step have crossed every barrier between the primary tumor and a new organ. But even then, their fate is not sealed.
Dormancy and Late Recurrence
Many cancer cells that reach a distant organ do not immediately start growing. Instead, they can enter a state of dormancy, sitting quietly as single cells or tiny clusters for months, years, or even decades. This is why some cancers recur long after apparently successful treatment. Breast cancer is especially notorious for late recurrence, sometimes reappearing 15 or 20 years after the original diagnosis. The mechanisms governing whether a dormant cell stays asleep or wakes up resemble the signals that control adult stem cells. Supportive cues from the surrounding tissue, such as Wnt and Notch signaling, can reactivate dormant cells, while inhibitory signals like BMP help keep them quiet.24PubMed Central. Mechanisms governing metastatic dormancy and reactivation These dormant cells are also sheltered by specialized niches in the tissue, which makes them particularly hard to target with chemotherapy that typically kills actively dividing cells.
Dormancy is one of the least well-understood stages of cancer progression, and it poses real clinical problems. A patient may be told they are cancer-free after surgery and chemotherapy, yet harbor thousands of dormant cells scattered in distant organs. We currently have no reliable way to detect these cells or to predict which patients will experience reactivation. Research into what triggers the dormancy-to-growth switch is one of the more active areas in cancer biology, because finding a way to keep cells dormant permanently would effectively prevent late-stage metastatic disease.
How Cancer Hides from the Immune System
Your immune system is remarkably good at detecting and destroying abnormal cells. Immune cells called T cells constantly patrol your tissues, and they can recognize and kill cancer cells that display abnormal proteins on their surface. So why do tumors survive? Cancer cells evolve multiple strategies to suppress or evade immune responses. One of the best-studied strategies involves a molecular handshake between a protein on the cancer cell’s surface called PD-L1 and a receptor on T cells called PD-1. In normal physiology, this interaction acts as a brake that prevents the immune system from attacking the body’s own healthy tissue. Cancer cells hijack this system by displaying PD-L1 on their surface, effectively telling approaching T cells to stand down.25PubMed Central. Regulatory mechanisms of PD-1/PD-L1 in cancers
This discovery led to the development of checkpoint inhibitor drugs, which block the PD-1/PD-L1 interaction and unleash T cells against the tumor. These therapies have produced dramatic responses in some patients with melanoma, lung cancer, and other tumor types. But they do not work for everyone, and researchers have been working to understand why. One emerging explanation involves regulatory T cells, a specialized immune cell population whose job is to tamp down immune activity. Checkpoint blockade can inadvertently activate these regulatory T cells within the tumor, actually intensifying the immune suppression it was supposed to lift. Studies in patients with skin cancer and lung cancer have shown that tumor-infiltrating regulatory T cells ramp up suppressive gene programs after checkpoint treatment, and this activation correlates with lack of response.26PubMed. PD-L1 checkpoint blockade promotes regulatory T cell activity that underlies therapy resistance In animal models, depleting regulatory T cells reversed resistance to PD-L1 blockade and allowed effector T cells to expand and attack the tumor.27PubMed. Regulatory T cells in cancer anti-PD-(L)1 therapy Combining checkpoint inhibitors with strategies that target regulatory T cells is an active area of clinical investigation.
Treatment Resistance and Tumor Evolution
By the time a tumor is diagnosed, it is not a single uniform population of identical cells. It is a patchwork of genetically distinct subpopulations, each with slightly different mutations. This diversity, called intra-tumor heterogeneity, is what makes cancer so difficult to treat. When chemotherapy, targeted therapy, or radiation kills the majority of cancer cells, the surviving minority often carries mutations that confer resistance. Those survivors then repopulate the tumor, and the new tumor is now resistant to the treatment that worked before. This process mirrors natural selection in a compressed timeframe: drug pressure acts as the selective force, and resistant clones are the “fittest” survivors.28PubMed. Clonal evolution and expansion associated with therapy resistance and relapse of colorectal cancer
The pattern creates a frustrating clinical reality. A patient responds well to a first-line treatment, the tumor shrinks, and then months later it rebounds, now unresponsive to the same drug. Second-line treatments may work for a while, but the same evolutionary cycle can repeat. This is why oncologists increasingly think of cancer management in terms of evolutionary strategy rather than simply choosing the strongest drug. Some researchers have even proposed “adaptive therapy” approaches that deliberately leave a small population of drug-sensitive cells alive, because those sensitive cells compete with resistant ones for resources and slow their takeover. The approach is still experimental, but it reflects how deeply the evolutionary framing has reshaped thinking about cancer treatment.
Physical Forces in Cancer Progression
Cancer is often discussed in terms of genes, proteins, and signaling molecules, but the physical environment matters too. Tumors exist in a mechanical world: growing tissue pushes against surrounding structures, blood flow exerts shear stress on circulating cells, and the stiffness of the tissue itself sends signals that alter cell behavior. Research has shown that mechanical forces, including matrix stiffness, compression, tension, and fluid shear stress, directly influence populations of cancer cells with stem-like properties, affecting whether they remain dormant, proliferate, or become more invasive.29PubMed Central. Effects of biomechanical forces on the biological behavior of cancer stem cells This is why the stiffened scaffold built by cancer-associated fibroblasts is not just structural support but an active participant in progression. As tissue stiffens, the increased mechanical stress activates growth and survival pathways in cancer cells that purely biochemical models would miss.
The Role of Microbes
A more recently appreciated player in cancer progression is the microbial community, both within the gut and within tumors themselves. The intestinal microbiome influences cancer development and progression through effects on inflammation, immune regulation, and metabolite production. Beyond the gut, bacteria have been found living inside tumors, forming what is called a tumor-associated microbiota. These intratumoral microbes can shape the local immune environment and influence how well or poorly the tumor responds to treatment.30PubMed. Targeting the gut and tumor microbiome in cancer treatment resistance Research into the microbiome and cancer is still in its relatively early stages, but it has already shown that antibiotic use during certain immunotherapies can reduce treatment effectiveness, and that specific bacterial species within tumors correlate with better or worse outcomes. The idea that the bacteria living in and around a tumor could be manipulated to improve treatment is being actively tested in clinical trials involving fecal transplants and engineered probiotics.
Why Large Animals Do Not Get More Cancer
If cancer is a disease of accumulated mutations, and mutations arise with each cell division, then you would expect that bigger animals with more cells and longer lifespans would get cancer far more often than small ones. A whale has trillions more cells than a mouse, and each one of those cells divides over a much longer lifetime. Yet cancer rates across species do not scale with body mass or lifespan. This puzzle, known as Peto’s Paradox, suggests that large, long-lived species have evolved enhanced cancer-suppression mechanisms.31PubMed Central. A phylogenetic review of cancer resistance highlights evolutionary solutions to Peto’s Paradox Elephants, for example, carry many extra copies of the TP53 gene, a master tumor suppressor. Naked mole-rats produce an unusually thick form of hyaluronic acid between their cells that appears to physically prevent unchecked cell growth. Studying these natural solutions to cancer is not just an academic curiosity. Understanding how evolution has solved the problem of cancer suppression in other species could eventually inform new prevention and treatment strategies in humans.